Company intelligence / Profile preview

Pharma Power Biotec Co., Ltd.

Ownership: Private
Employees: ~40
Development stage: Other

Overview

The company’s lead asset is Radion™ PDT for the treatment of oral precancerous lesions. A Phase II clinical trial has been completed evaluating efficacy and safety in patients with oral verrucous hyperplasia or erythroleukoplakia. No published pivotal results yet; highest phase reached is Phase II.

Therapeutic areas: OncologyEndocrinology
Modalities: Photodynamic therapy (PDT)Mucoadhesive thermo-responsive medicament-carrier compositionsHealth foods for metabolic health/diabetes/weight loss
Industry: Biotech

Drug pipeline

2 assets

PPB-R-203

Preclinical

1 more asset in the full pipeline.

Partnerships

Industrial Technology Research Institute (ITRI)National Taiwan University (NTU)Chung Shan Medical University (CSMU)Taipei Medical University (TMU)Kaohsiung Medical University (KMU)

Beyond the preview

Go deeper on Pharma Power Biotec Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharma Power Biotec Co., Ltd..